Aeras Global TB Vaccine Foundation

aka Aeras   |   Rockville, MD   |  www.aeras.org
This organization has not appeared on the IRS Business Master File in a number of months. It may have merged with another organization or ceased operations.
This organization is not registered with the IRS.

Mission

Aeras is a non-profit product development organization dedicated to the development of effective tuberculosis (TB) vaccines and biologics to prevent TB across all age groups in an affordable and sustainable manner.

Ruling year info

1999

Principal Officer

Tom Evans M.D.

Main address

1405 Research Blvd

Rockville, MD 20850 USA

Show more contact info

Formerly known as

Aeras Global TB Vaccine Foundation

EIN

52-2044704

NTEE code info

Specifically Named Diseases Research (H80)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2020, 2019 and 2018.
Register now

Communication

Blog

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Development of new recombinant live BCG vaccine candidates

Recombinant BCG (rBCG) strains are being constructed with enhanced immunogenicity based on the capacity to escape the endosome and the overexpression of select tuberculosis antigens. The lead candidate, AERAS-406 also includes a pro-apoptotic factor. The TB antigens 85A, 85B, 10 4, RV3407, AERAS-407 is in pre-clinical development.

Population(s) Served

Where we work

This profile needs more info.

If it is your nonprofit, add geographic service areas to create a map on your profile.

Login and update

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

The overall goal of Aeras is to markedly lower tuberculosis incidence and prevalence through vaccination. This goal can likely best be achieved by developing a portfolio of vaccines that protect individuals from infection, prevent infected individuals from progressing to active disease, and decrease the transmission capacity of those with active disease. Aeras has outlined four primary goals for 2012-2016: 1)Complete clinical trials of current candidates; 2) Build a robust and diverse pipeline of new TB vaccine candidates; 3) refine TB vaccine candidate selection and advancement; and 4) Strengthen and diversify the funding base by building new collaborations and partnerships that advance tuberculosis vaccine development.

Aeras operates on a partnership model and supports the development of the world’s most promising TB vaccine candidates by working in collaboration with a diverse global community of scientists and researchers from academia, industry, governments and funders.

With world-class in-house capacity in preclinical research, immunology, regulatory affairs, clinical development and vaccine manufacturing, Aeras is uniquely qualified to serve as a critical translational bridge from research to licensure and from the laboratory to manufacturing.

Aeras and its partners have six TB vaccines undergoing clinical testing and there is a robust pipeline of early stage candidates in the pipeline being evaluated against globally agreed upon stringent scientific criteria for advancement. Aeras and its partners published a framework for TB vaccine development for the next 10 years in March 2012. In February 2012, Aeras and its partners published findings from a major TB vaccine clinical trial. While the trial proved the vaccine to be not effective in preventing TB in infants, it added significanlty to the body of knowledge on TB vaccine and its findings are being applied to other candidates in development.

Financials

Aeras Global TB Vaccine Foundation
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Aeras Global TB Vaccine Foundation

Board of directors
as of 11/12/2013
SOURCE: Self-reported by organization
Board chair

R. Gordon Douglas

No affiliation

Peter Barton Hutt

Covington & Burling

R. Gordon Douglas Chairman

No Affiliation

Hoosen Coovadia Director of Maternal, Adolescent and Child Health and Emeritus Professor of Paediatrics and Child Health

University of the Witwatersrand and University of KwaZulu-Natal

Regina Rabinovich ExxonMobil Malaria Scholar in Residence

Harvard School of Public Health

Jim Connolly Former President & CEO

Aeras

Barry Bloom Distinguished Service Professor

Harvard University

Marja Esveld Senior Advisor, Research and Innovation

Netherlands Ministry of Health

Gustavo Gonzalez-Canali Physician

Medecin des Hôpitaux

Wayne Pisano President and CEO, VaxInnate

Gerd Zettlmeissl Former Chief Executive Officer

Intercell AG

Lota Zoth Former Senior VP and CFO

MedImmune, Inc.